SCHEMBL16394288

SCHEMBL16394288

Cn1cc(-c2nccn3nc(Nc4ccc5c(c4)NS(=O)(=O)C5)nc23)cn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.64
EIF2AK4 Q9P2K8 1/20 0.64
AXL P30530 3/20 0.38
JAK2 O60674 3/20 0.38
JAK3 P52333 3/20 0.38
PTK2 Q05397 3/20 0.38
CDK2 P24941 8/20 0.37
TTK P33981 2/20 0.37
CCNA2 P20248 1/20 0.37
WNT1 P04628 1/20 0.37
GSK3B P49841 1/20 0.37
DYRK1A Q13627 1/20 0.37
CCNE2 O96020 7/20 0.36
CCNE1 P24864 7/20 0.36
CCNB2 O95067 6/20 0.36
CDK1 P06493 6/20 0.36
CCNB1 P14635 6/20 0.36
CDK5 Q00535 6/20 0.36
CDK5R1 Q15078 6/20 0.36
CCNB3 Q8WWL7 6/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15212844 0.93 SYK (0.60) SYKEIF2AK4AXLJAK2JAK3
SCHEMBL16407129 0.86 SYK (0.69) SYKEIF2AK4AXLJAK2JAK3
SCHEMBL15221133 0.84 SYK (0.69) SYKEIF2AK4JAK2CDK2TTK
SCHEMBL15212841 0.82 SYK (0.56) SYKEIF2AK4AXLJAK2JAK3
SCHEMBL15210757 0.82 SYK (0.78) SYKEIF2AK4AXLJAK2JAK3
SCHEMBL16407132 0.82 SYK (0.78) SYKEIF2AK4AXLJAK2JAK3
SCHEMBL19982828 0.81 SYK (0.60) SYKEIF2AK4AXLJAK2JAK3
SCHEMBL20041 0.81 SYK (0.64) SYKEIF2AK4AXLJAK2PTK2
SCHEMBL15221230 0.80 SYK (0.71) SYKEIF2AK4AXLJAK2JAK3
SCHEMBL15212605 0.80 SYK (0.71) SYKEIF2AK4AXLJAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US claimed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 EP disclosed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 EP disclosed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 US disclosed
US-9120804-B2 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors MERCK PATENT GMBH (DE) 2015-09-01 US disclosed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US disclosed
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025058-A1 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS SYK, EIF2AK4, BTK SYK 1/4885EIF2AK4 2/4885AXL 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.